Browse the corpus

Gonococcal arthritis is a severe manifestation of disseminated gonococcal infection caused by Neisseria gonorrhoeae and represents a systemic complication of untreated or inadequately treated mucosal infection. Although relatively uncommon, disseminated disease carries substantial morbidity when diagnosis is delayed. This course outlines the clinical presentations of gonococcal arthritis, which often include an arthritis–dermatitis syndrome with migratory polyarthralgia, tenosynovitis, and characteristic skin lesions, or a purulent septic arthritis, most commonly affecting the knee or wrist, as well as its evaluation, which includes microbiologic studies as genitourinary symptoms are frequently absent and early features may mimic other inflammatory or infectious conditions. This activity reviews the clinical patterns, diagnostic strategies, and management of gonococcal arthritis and disseminated gonococcal infection to assist in the prompt initiation of appropriate antimicrobial therapy essential to prevent permanent joint damage and systemic complications. Participants will also gain an understanding of pathophysiology, antimicrobial resistance considerations, and evidence-based treatment approaches, including joint drainage and partner management. This activity for healthcare professionals is designed to enhance the learner's competence in adhering to treatment guidelines, promoting patient education, and coordinating partner notification, performing the recommended evaluation, and implementing an appropriate interprofessional approach when managing this condition to improve outcomes and reduce complications. Objectives: Identify the clinical features associated with gonococcal arthritis. Assess patients with suspected disseminated gonococcal infection using appropriate microbiologic testing. Select guideline-based antimicrobial therapy based on clinical response to therapy. Collaborate effectively within the interprofessional healthcare team to improve care coordination and outcomes for patients with gonococcal arthritis. Access free multiple choice questions on this topic.

Gonococcal arthritis represents a manifestation of disseminated gonococcal infection caused by Neisseria gonorrhoeae and reflects a systemic complication of untreated or inadequately treated mucosal gonococcal infection. Despite the relatively low incidence of disseminated disease, gonococcal arthritis carries substantial morbidity when recognition and treatment are delayed.[1] Clinical presentation most commonly follows 1 of 2 patterns: dermatitis–arthritis syndrome or purulent monoarthritis. Early manifestations often lack specificity and may resemble viral illness, inflammatory arthritis, or other forms of septic arthritis, which contributes to delays in diagnosis. Prompt clinical recognition, accurate microbiologic confirmation, and initiation of appropriate antimicrobial therapy remain essential to reducing the risk of permanent joint damage and systemic complications.[2][3]

Gonococcal arthritis is caused by Neisseria gonorrhoeae, a gram-negative, oxidase-positive intracellular diplococcus transmitted primarily through sexual contact. The organism can infect multiple mucosal surfaces, most commonly the urethra, cervix, rectum, and pharynx, where infection is frequently asymptomatic, particularly in females and at extragenital sites. Disseminated gonococcal infection develops in approximately 0.5% to 3% of individuals with gonorrhea. Following mucosal colonization, N gonorrhoeae may invade the bloodstream, leading to bacteremia and immune-mediated phenomena.[4] N gonorrhoeae expresses multiple virulence factors that enhance its ability to survive in the host and disseminate. These include serum-resistant porin proteins (particularly PorB1a), strains with the arginine–hypoxanthine–uracil auxotype, and specific genetic islands that promote survival in the bloodstream. Additional mechanisms, eg, variation in Opa proteins, lipid A modification, and antigenic and phase variation of pili, facilitate immune evasion, mucosal invasion, and systemic spread. Collectively, these microbial adaptations increase the likelihood of dissemination and contribute to the development of gonococcal arthritis.[5][6][7][8]

In the United States, Neisseria gonorrhoeae remains a significant public health concern. Provisional Centers for Disease Control and Prevention (CDC) surveillance data indicate that reported sexually transmitted infections, including gonorrhea, declined in 2024 for the third consecutive year, with more than 2.2 million combined cases of chlamydia, gonorrhea, and syphilis reported nationwide and an approximately 10% decrease in gonorrhea cases compared with the previous year. Despite this recent decline, the overall burden of gonorrhea and other sexually transmitted infections (STIs) remains substantially higher than a decade ago, highlighting persistent transmission and ongoing public health impact.[CDC. Sexually Transmitted Infections Surveillance, 2024 (Provisional)] Disseminated gonococcal infection can occur at any age, but most cases are reported in individuals younger than 40 years. Several studies suggest that disseminated gonococcal infection occurs more frequently in females than in males.[4] Multiple host-related factors increase the risk of dissemination, including female sex, pregnancy, menstruation, systemic lupus erythematosus, HIV infection, intravenous drug use, and the use of complement-inhibiting therapies (eg, eculizumab).[9][10] Both congenital and acquired complement deficiencies, particularly deficiencies in the terminal complement components (C5–C9), are strongly associated with increased susceptibility to invasive gonococcal disease due to impaired serum bactericidal activity.[11][4]

Clinical Manifestations of Gonococcal Arthritis The clinical manifestations of disseminated gonococcal infection are commonly described as either of the 2 follownig overlapping patterns: Arthritis–dermatitis syndrome (60%): Characterized by migratory polyarthralgia, tenosynovitis, and skin lesions Purulent (septic) arthritis syndrome (40%): Presenting as acute monoarthritis [12][2][13] These patterns are not mutually exclusive, and many patients demonstrate clinical features of both. Genitourinary symptoms may be absent, particularly in women. The interval between initial gonococcal acquisition and the onset of systemic symptoms can vary widely, ranging from 1 day to 3 months.[13] Arthritis-dermatitis syndrome The arthritis–dermatitis syndrome typically develops 1 to 4 weeks following the initial gonococcal infection and is often accompanied by nonspecific systemic symptoms, eg, fever, malaise, and myalgias. Migratory polyarthralgia or polyarthritis is the most common presenting complaint and usually involves multiple joints. The pattern of joint involvement is characteristically asymmetric and more often affects the upper extremities than the lower extremities, with the wrists, elbows, knees, and ankles most frequently involved. In some individuals, symptoms resolve spontaneously, whereas in others the illness progresses to true septic arthritis affecting 1 or more joints. Dermatitis is seen in approximately 75% of cases, but is frequently underrecognized because the lesions are typically painless and nonpruritic.[14] The rash most commonly consists of small pustules, papules, or vesicles, though hemorrhagic macules, papules, bullae, and nodules have also been reported. Rarely, more severe dermatologic manifestations, eg, cellulitis, abscess formation, petechiae, purpura, vasculitis, or necrotizing soft-tissue infection, may occur.[2][15][13] Notably, tenosynovitis is a hallmark of disseminated gonococcal infection and is often seen along the extensor surfaces of the wrists and hands, as well as around the metacarpophalangeal joints, ankles, and knees. When the fingers are diffusely involved, a sausage-like appearance (dactylitis) may be observed.[2][13] Purulent (septic) arthritis syndrome

Notably, tenosynovitis is a hallmark of disseminated gonococcal infection and is often seen along the extensor surfaces of the wrists and hands, as well as around the metacarpophalangeal joints, ankles, and knees. When the fingers are diffusely involved, a sausage-like appearance (dactylitis) may be observed.[2][13] Purulent (septic) arthritis syndrome In the localized form, symptoms usually develop days to weeks after the initial infection. Patients typically present with acute inflammatory arthritis involving 1 or occasionally multiple joints. The affected joint is characteristically painful, swollen, warm, and erythematous, with a limited range of motion. The knee is most commonly involved, followed by the wrist, ankle, and elbow.[13]

A comprehensive diagnostic evaluation remains essential in patients with suspected disseminated gonococcal infection, as cultures from disseminated sites often yield negative results.[16] Any isolate of Neisseria gonorrhoeae obtained from culture should undergo antimicrobial susceptibility testing due to rising global resistance and the importance of guiding therapy.[CDC. Gonorrhea Laboratory Information. 2024] Blood Cultures Patients with suspected disseminated gonococcal infection should have at least 2 sets of blood cultures collected. Although reported positivity rates range from approximately 4% to 70%, positive blood cultures confirm the diagnosis and help distinguish disseminated gonococcal infection from other causes of septic arthritis. Mucosal Site Testing Because many patients with disseminated gonococcal infection have asymptomatic mucosal infection, NAAT and culture specimens from urogenital and extragenital mucosal sites should be collected, in addition to culture specimens from disseminated sites of infection (eg, skin, synovial fluid, blood, or CSF). All N gonorrhoeae isolates from disseminated gonococcal infection cases should be tested for antimicrobial susceptibility, which necessitates culture.[17][18] Synovial Fluid Analysis All patients with suspected disseminated gonococcal infection who have an accessible joint effusion should undergo synovial fluid aspiration. Fluid should be sent for cell count and differential, Gram stain, bacterial culture, and NAAT. Gram stain may show intracellular gram-negative diplococci, although sensitivity is low. The cell count is usually higher than 50,000 WBC/µL, and polymorphonuclear leukocytes [PMNs] typically account for more than 90%. Synovial biopsy, when performed, reveals acute suppurative synovitis without distinctive histologic features differentiating it from other bacterial arthritides.[19] Skin Lesion Testing Skin lesions associated with disseminated gonococcal infection often prove difficult to sample and yield low diagnostic returns. When pustular lesions appear, specimens may undergo Gram stain, culture, or NAAT, although cultures are positive in only a minority of cases. Screening Screening for coinfections, including HIV, syphilis, and chlamydia, should accompany the diagnostic evaluation.

Given the increasing concern about antimicrobial resistance in Neisseria gonorrhoeae, specimens for microbiologic testing should be obtained before initiating antibiotics whenever feasible. However, treatment should not be delayed when clinical suspicion for disseminated gonococcal infection is high. Early initiation of therapy is essential to prevent complications such as joint destruction. Initial Antimicrobial Therapy Current guideline-based therapy for disseminated gonococcal infection with arthritis includes ceftriaxone administered at a dose of 1 g intravenously or intramuscularly every 24 hours.[20] Treatment should continue for at least 7 days and until clinical signs and symptoms resolve or nearly resolve. Transition to oral therapy may occur after sustained clinical improvement and confirmation of antimicrobial susceptibility. Because coinfection with Chlamydia trachomatis occurs frequently, empiric treatment for chlamydia should accompany therapy unless diagnostic testing excludes infection.[20][21] Recommended options include doxycycline 100 mg orally twice daily for 7 days or azithromycin 1 g orally as a single dose, based on current guidance and individual patient factors. Management of Arthritis–Dermatitis Syndrome Patients presenting with arthritis–dermatitis syndrome, characterized by tenosynovitis, dermatitis, and migratory arthralgia with minimal or absent joint effusion, often show rapid clinical improvement following initiation of appropriate antimicrobial therapy. After 24 to 48 hours of improvement with ceftriaxone, treatment may continue with daily intramuscular dosing. In carefully selected patients who demonstrate a prompt clinical response and lack purulent arthritis, oral step-down therapy, eg, cefixime, may be considered only when susceptibility testing confirms sensitivity. Because many laboratories lack routine gonococcal susceptibility testing and resistance patterns continue to evolve, completion of therapy with a third-generation cephalosporin remains appropriate for most patients. Management of Purulent Arthritis

Patients presenting with arthritis–dermatitis syndrome, characterized by tenosynovitis, dermatitis, and migratory arthralgia with minimal or absent joint effusion, often show rapid clinical improvement following initiation of appropriate antimicrobial therapy. After 24 to 48 hours of improvement with ceftriaxone, treatment may continue with daily intramuscular dosing. In carefully selected patients who demonstrate a prompt clinical response and lack purulent arthritis, oral step-down therapy, eg, cefixime, may be considered only when susceptibility testing confirms sensitivity. Because many laboratories lack routine gonococcal susceptibility testing and resistance patterns continue to evolve, completion of therapy with a third-generation cephalosporin remains appropriate for most patients. Management of Purulent Arthritis Patients with purulent gonococcal arthritis generally require parenteral therapy for a longer duration, typically 7 to 14 days, depending on clinical response. Those with immunocompromising conditions or slower improvement may require extended courses. Joint drainage is a critical component of treatment for purulent gonococcal arthritis and may be accomplished through repeated needle aspiration, arthroscopic drainage, or surgical drainage when less invasive approaches are ineffective. Failure to adequately drain the joint may lead to persistent infection and long-term joint damage.[20] Supportive care plays an important role and includes analgesics, anti-inflammatory medications, and early mobilization and physical therapy once pain and swelling improve.[20] Partner Management All sexual partners within the preceding 60 days should be notified, evaluated, and treated to prevent reinfection and further transmission. Patients should abstain from sexual activity for at least 7 days after completing therapy and until all sexual partners have been treated.[20][22]

Differential diagnoses that should also be considered when evaluating gonococcal arthritis include: Nongonococcal septic arthritis (eg, Staphylococcus aureus): This condition presents with acute monoarticular joint pain, swelling, warmth, and elevated inflammatory markers, closely mimicking purulent gonococcal arthritis. Infective endocarditis: Patients with infective endocarditis present with fever, bacteremia, and immune-mediated or septic arthritis, sometimes accompanied by rash and systemic symptoms similar to disseminated gonococcal infection. Reactive arthritis: This condition causes asymmetric inflammatory arthritis following genitourinary or gastrointestinal infection and may be mistaken for postgonococcal joint disease. Rheumatoid arthritis: Patients with rheumatoid arthritis may present with symmetric polyarthritis, morning stiffness, and elevated inflammatory markers, which overlap with migratory inflammatory joint symptoms. Systemic lupus erythematosus: This condition frequently causes migratory arthralgias, rash, and systemic symptoms that can resemble the arthritis–dermatitis syndrome. Viral arthritis (eg, parvovirus B19, hepatitis B): Patients with viral arthritis often present with acute symmetric polyarthritis and systemic symptoms that can clinically resemble inflammatory or infectious arthritis. Crystal-induced arthritis (gout, pseudogout): This condition causes sudden-onset, intensely painful monoarthritis with erythema and swelling, which can be difficult to distinguish from septic arthritis. Lyme arthritis: Patients with Lyme arthritis commonly present with monoarticular or oligoarticular arthritis, especially of the knee, and can mimic infectious arthritis in endemic regions.[23][3][12]

With early diagnosis and appropriate antibiotic therapy, the prognosis for gonococcal arthritis is excellent. Most patients recover fully without long-term joint damage. Delayed treatment, however, may result in chronic pain, reduced range of motion, or irreversible joint destruction.[23]

Patients benefit from an interprofessional approach, which may include: Infectious disease specialists Rheumatologists Orthopedic surgeons Primary care and sexual health clinicians Clinicians are recommended to report treatment failure to the CDC within 24 hours of laboratory culture confirmation of the diagnosis of antimicrobial-resistant N gonorrhoeae.[24]

Deterrence and patient education play central roles in reducing the risk of gonococcal arthritis and its complications. Clinicians should educate patients on the importance of early evaluation and treatment of sexually transmitted infections, as untreated or inadequately treated mucosal gonococcal infection can progress to disseminated disease with joint involvement. Prevention strategies include: Consistent condom use Routine screening in high-risk populations Prompt evaluation and treatment of STIs Partner notification and treatment Education regarding the asymptomatic nature of many gonococcal infections Abstain from sexual activity for at least 7 days after completing therapy and until all sexual partners have been treated. Counseling should also emphasize prompt testing following potential exposure, even in the absence of symptoms. Patients should receive clear instructions on adherence to prescribed antimicrobial therapy and on completing the full treatment course. Education regarding partner notification, recognition of warning signs (eg, joint pain, swelling, rash, or fever), and timely follow-up care supports prevention of reinfection, limits transmission, and reduces the likelihood of permanent joint damage or systemic complications.

Gonococcal arthritis represents a serious manifestation of disseminated gonococcal infection caused by Neisseria gonorrhoeae, arising from untreated or inadequately treated mucosal infection. Although relatively uncommon, disseminated gonococcal infection carries significant morbidity if recognition and treatment are delayed. Clinical presentations typically include an arthritis–dermatitis syndrome with migratory polyarthralgia, tenosynovitis, and skin lesions, or purulent monoarthritis affecting joints such as the knee or wrist. Early symptoms often mimic viral illness, inflammatory arthritis, or other septic arthritides, complicating diagnosis. Timely microbiologic confirmation, appropriate antimicrobial therapy, joint drainage when necessary, and partner management are essential to prevent joint destruction, systemic complications, and reinfection. Rising antimicrobial resistance further underscores the need for culture-based susceptibility testing to guide therapy. Effective management of gonococcal arthritis requires coordinated interprofessional care. Physicians and advanced practitioners must accurately recognize clinical patterns, order appropriate diagnostic testing, and initiate guideline-based antimicrobial therapy. Nurses support specimen collection, administer parenteral therapy, monitor clinical response, and provide patient education regarding adherence, partner notification, and safe sexual practices. Pharmacists ensure correct antimicrobial selection, dosing, and monitoring for potential drug interactions. Collaboration among clinicians, laboratory personnel, and public health professionals enhances early detection, optimizes patient-centered care, improves outcomes, and reduces the risk of long-term joint damage or systemic complications, reinforcing team performance and patient safety.